Cross-talk between phospholipase C and phosphoinositide 3-kinase signalling pathways

Autor: Ian H. Batty, Hickinson Dm, C P Downes

Publikováno v: Biochemical Society Transactions. 25:1132-1137

1321N1 astrocytoma cells have proved a valuable model system in which to study interactions between two major PtdIns (4,5) P2-utilizing signaling pathways, since they possess receptor populations which elicit independent activation of PI 3-kinase and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea65e181a7e1a1286c351aae4e34a6dc
https://doi.org/10.1042/bst0251132

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors.

Autor: Barlaam B; Centre de Recherches, AstraZeneca , Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims, Cedex 2, France., Anderton J; Oncology iMed, AstraZeneca , Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Ballard P; Oncology iMed, AstraZeneca , Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Bradbury RH; Oncology iMed, AstraZeneca , Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Hennequin LF; Centre de Recherches, AstraZeneca , Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims, Cedex 2, France., Hickinson DM; Oncology iMed, AstraZeneca , Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Kettle JG; Oncology iMed, AstraZeneca , Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Kirk G; Oncology iMed, AstraZeneca , Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Klinowska T; Oncology iMed, AstraZeneca , Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Lambert-van der Brempt C; Centre de Recherches, AstraZeneca , Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims, Cedex 2, France., Trigwell C; Oncology iMed, AstraZeneca , Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Vincent J; Oncology iMed, AstraZeneca , Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Ogilvie D; Oncology iMed, AstraZeneca , Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom.

Publikováno v: ACS medicinal chemistry letters [ACS Med Chem Lett] 2013 May 31; Vol. 4 (8), pp. 742-6. Date of Electronic Publication: 2013 May 31 (Print Publication: 2013).

Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters.

Autor: Morrow CJ; Paterson Institute for Cancer Research, University of Manchester, Manchester Cancer Research Centre and Manchester Academic Health Sciences Centre, Manchester, United Kingdom. cmorrow@picr.man.ac.uk, Ghattas M, Smith C, Bönisch H, Bryce RA, Hickinson DM, Green TP, Dive C

Publikováno v: Cancer research [Cancer Res] 2010 Jul 15; Vol. 70 (14), pp. 5931-41. Date of Electronic Publication: 2010 Jun 15.

Identification of biomarkers in human head and neck tumor cell lines that predict for in vitro sensitivity to gefitinib.

Autor: Hickinson DM; Fomerly of AstraZeneca, Alderly Park, Macclesfield, UK., Marshall GB, Beran GJ, Varella-Garcia M, Mills EA, South MC, Cassidy AM, Acheson KL, McWalter G, McCormack RM, Bunn PA, French T, Graham A, Holloway BR, Hirsch FR, Speake G

Publikováno v: Clinical and translational science [Clin Transl Sci] 2009 Jun; Vol. 2 (3), pp. 183-92.